David W. Hein, Ph.D.


B.S., Chemistry, University of Wisconsin-Eau Claire
Ph.D., Pharmacology, University of Michigan

Curriculum Vitae

Current Positions:

Peter K. Knoefel Endowed Chair of Pharmacology and Toxicology
Professor and Chairman, Department of Pharmacology and Toxicology
Distinguished University Scholar
Director, NIEHS Environmental Health Sciences Training Program
Director, NCI Cancer Education Program

Contact Information:

Kosair Charities CTR – Room 303
University of Louisville Health Sciences Center
505 South Hancock Street
Louisville, KY  40202-1617
Telephone :  502-852-6252

Email :  david.hein@louisville.edu



Research Description:

Dr. Hein serves as Peter K. Knoefel Endowed Chair of Pharmacology, Professor and Chairman of the Department of Pharmacology & Toxicology, and Distinguished University Scholar at the University of Louisville.  He leads four National Institutes of Health-funded training programs: University of Louisville Cancer Education Program funded by the National Cancer Institute; University of Louisville pre- and post-doctoral training program in environmental health sciences funded by the National Institutes of Environmental Health Sciences (NIEHS); University of Louisville Superfund Research Center Training Core funded by NIEHS; and University of Louisville Hepatobiology and Toxicology CoBRE Faculty Career Development Program funded by the National Institute of General Medical Sciences.  From 2009-2017 he served as Associate Provost for Strategic Planning and Vice Provost for Academic Strategy and led development and implementation of PhD partnerships with Wenzhou Medical University, Jilin University, Cairo University and Ain Shams University.  Numerous students have completed thesis and dissertation research training in his laboratory and he contributes towards instruction of undergraduate, graduate and health professional students. Prior to recruitment to the University of Louisville, Dr. Hein served as founding director of the National Institutes of Health-funded Minority Biomedical Research Support Program at Morehouse School of Medicine, chair of the Departments of Pharmacology & Toxicology at Morehouse School of Medicine and the University of North Dakota School of Medicine and Health Sciences.  He has served as reviewer of grant proposals for the National Institutes of Health and other funding agencies and a consultant to numerous companies across the USA and the world.

Dr. Hein’s research program includes studies of the molecular epidemiology of cancer susceptibility, pharmacogenetics, genomics, personalized medicine, and functional genomics. The research in molecular epidemiology identifies individuals genetically susceptible to the development of cancer from environmental and occupational chemicals in order to focus treatment and prevention public health strategies on those at greatest risk. The research in pharmacogenetics/genomics and personalized/precision medicine improves our understanding of the genetic causes for drug failure and/or drug toxicity in order to optimize clinical drug therapy for each individual patient. The research in functional genomics improves understanding of the mechanistic and clinical consequences of genetic variation in the biotransformation of carcinogens and drugs. The research program has been funded continuously since 1983 by over 75 grants and contracts totaling over $50M from the National Institutes of Health and other federal and private foundations and industry. He has coauthored about 250 peer-reviewed journal articles and book chapters, 75 gene sequences, and 600 abstracts with over 13,500 citations (h-index=59) in the scientific literature.

Literature Cited:

  1. Carlisle SM, Trainer PT, Yin X, Doll MA, Stepp MW, States JC, Zhang X, Hein DW.  Untargeted polar metabolomics of transformed MDA-MB-231 breast cancer cells expressing varying levels of human arylamine N-acetyltransferase 1.  Metabolomics 2016 Jul;12(7). pii: 111. (Epub 2016 Jun 21) (PubMed)27872580. PMCID: PMC5115175.
  2. Stepp MW, Doll MA, Samuelson DJ, Sanders MG, States JC, Hein DW.  Congenic rats with higher arylamine N-acetyltransferase 2 activity exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen metabolism.  BMC Cancer 2017 Mar 31;17(1):233. (PubMed)28359264. PMCID: PMC5374573.
  3. Hein DW, Doll MA.  Role of N-acetylation polymorphism in solithromycin metabolism.   Pharmacogenomics 2017 Jun;18(8):765-72. (Epub 2017 Apr 24) (PubMed)28625123.  PMCID: PMC570491.
  4. Doll MA, Hein DW.  Genetic heterogeneity among slow acetylator N-acetyltransferase 2 phenotypes in cryopreserved human hepatocytes.  Archives of Toxicology 2017 Jul;91(7):2655-61. (Epub 2017 May 17)(PubMed)28516247. PMCID: PMC5713641. [Subject of special commentary published in Archives of Toxicology 2017;91:4019-20] (PubMed)
  5. Hein DW, Doll MA.  Catalytic properties and heat stabilities of novel recombinant human N-acetyltransferase 2 allozymes support existence of genetic heterogeneity within the slow acetylator phenotype.  Archives of Toxicology2017 Aug;91(8):2827-35.(Epub 2017 May 18)   (PubMed)29623442. PMCID: PMC5710007.
  6. Hein DW, Doll MA.  Rabbit N-acetyltransferase 2 genotyping method to investigate role of acetylation polymorphism on N- and O-acetylation of aromatic and heterocyclic amine carcinogens.  Archives of Toxicology 2017;91:3185-8. (Epub 2017 May 23) (PubMed)28536864.PMCID: PMC5700865.
  7. Allen CE, Doll MA, Hein DW.  N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes.  Drug Metabolism and Disposition 2017 Dec;45(12):1276-81. (Epub 2017 October 10)  (PubMed)29018032.  PMCID: PMC5706087.
  8. Hein DW, Kidd LR.  Design and success of a 21st century cancer education program at the University of Louisville.  Journal of Cancer Education2018 Apr;33(2):298-308. (Epub 2016 Jul 30)(PubMed)27474114. [PMCID:  PMC5280580]
  9. Salazar-González RA, Turiján-Espinoza E,Hein DW, Niño-Moreno PC, Romano-Moreno S, Milán-Segovia RC, Portales-Pérez DP.  Arylamine N-acetyltransferase 1 in situ N-acetylation on CD3+ peripheral blood mononuclear cells correlate with NATb mRNA and NAT1 haplotype.  Archives of Toxicology 2018 Feb;92(2):661-8. (Epub 2017 Oct 17) (PubMed)29043425.
  10. Hein DW, Zhang X, Doll MA.  Role of N-acetyltransferase 2 acetylation polymorphism in 4, 4’-methylene bis (2-chloroaniline) biotransformation.  Toxicology Letters 2018 Feb;283:100-5.  (Epub 2017 Nov 24) (PubMed)29180287.  PMCID: PMC5745265.
  11. Zhang X, Carlisle SM, Doll MA, Martin RCG, States JC, Klinge CM, Hein DW.  High N-acetyltransferase 1 (NAT1) expression is associated with estrogen receptor expression in breast tumors, but is not under direct regulation by estradiol, 5α-androstane-3β,17beta-diol, or dihydrotestosterone in breast cancer cells.  Journal of Pharmacology and Experimental Therapeutics 2018 Apr;365(1):84-93. (Epub 2018 Jan 16)(PubMed)29339455.PMCID: PMC5830641.
  12. Stepp MW,Doll MA, Carlisle SM, States JC, Hein DW.  Genetic and small molecule- inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.  Molecular Carcinogenesis2018 Apr;57(4):549-58.(Epub 2018 Feb 3) (PubMed)29315819. PMCID: PMC5832614].
  13. Carlisle SM, Hein DW.  Retrospective analysis of estrogen receptor 1 and N-acetyltransferase  gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines.  International Journal of Oncology 2018 Aug;53(2):694-702. (Epub 2018 Jun 11) (PubMed)29901116.  PMCID: PMC6017241.
  14. Carlisle SM, Trainor PJ, Doll MA, Stepp MW, Klinge CM, Hein DW.  Knockout of human arylamine N-acetyltransferase 1 (NAT1) in MDA-MB-231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity.  Molecular Carcinogenesis 2018 Jul 2.  doi: 10.1002/mc.22869. (Epub ahead of print)  (PubMed)29964355.
  15. Salazar-González RA, Turiján-Espinoza E, Hein DW, Milán-Segovia RC, Uresti-Rivera EE, Portales-Pérez, D.P.  Expression and genotype-dependent catalytic activityof N-acetyltransferase 2 (NAT2) in peripheral blood mononuclear cells and its modulation by Sirtuin 1.  Biochemical Pharmacology 2018 Aug 24.  doi: 10.1016/j.bcp.2018.08.034. (Epub ahead of print) (PubMed)30149019.

PubMed Information